Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Cancer, Papillary 2Sarcoma 2Salivary Gland Neoplasms 2Brain Neoplasms 2Wilms Tumor 1Sarcoma, Ewing 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neuroblastoma 1Nephroma, Mesoblastic 1Neoplasm Metastasis 1Melanoma 1Medulloblastoma 1Lymphoma, Large-Cell, Anaplastic 1Head and Neck Neoplasms 1Glioma 1Colorectal Neoplasms 1Cholangiocarcinoma 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Thyroid Cancer Patients Who Received Target Therapy 1

Interventions

trametinib 1selpercatinib 1pralsetinib 1lenvatinib 1larotrectinib 1entrectinib 1dabrafenib 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Thyroid Cancer Patients Who Received Target Therapy × entrectinib × Endocrine × Clear all
NCT06195228 2025-08-14

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Fudan University

Phase 4 Recruiting
800 enrolled
EndocrineHead & Neck

Advanced Thyroid Cancer Patients Who Received Target Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡